Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
2.
Oncogene ; 36(14): 1911-1924, 2017 04 06.
Artigo em Inglês | MEDLINE | ID: mdl-27748763

RESUMO

MYC genes have both essential roles during normal development and exert oncogenic functions during tumorigenesis. Expression of a dominant-negative allele of MYC, termed OmoMYC, can induce rapid tumor regression in mouse models with little toxicity for normal tissues. How OmoMYC discriminates between physiological and oncogenic functions of MYC is unclear. We have solved the crystal structure of OmoMYC and show that it forms a stable homodimer and as such recognizes DNA in the same manner as the MYC/MAX heterodimer. OmoMYC attenuates both MYC-dependent activation and repression by competing with MYC/MAX for binding to chromatin, effectively lowering MYC/MAX occupancy at its cognate binding sites. OmoMYC causes the largest decreases in promoter occupancy and changes in expression on genes that are invaded by oncogenic MYC levels. A signature of OmoMYC-regulated genes defines subgroups with high MYC levels in multiple tumor entities and identifies novel targets for the eradication of MYC-driven tumors.


Assuntos
Neoplasias/genética , Fragmentos de Peptídeos/fisiologia , Regiões Promotoras Genéticas , Proteínas Proto-Oncogênicas c-myc/antagonistas & inibidores , Proteínas Proto-Oncogênicas c-myc/metabolismo , Proteínas Supressoras de Tumor/fisiologia , Sítios de Ligação , Células Cultivadas , DNA/metabolismo , Regulação Neoplásica da Expressão Gênica/genética , Genes Dominantes , Humanos , Modelos Moleculares , Neoplasias/patologia , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/genética , Fragmentos de Peptídeos/metabolismo , Multimerização Proteica , Proteínas Proto-Oncogênicas c-myc/química , Proteínas Proto-Oncogênicas c-myc/genética , Proteínas Proto-Oncogênicas c-myc/fisiologia , Homologia de Sequência , Transcriptoma , Proteínas Supressoras de Tumor/química , Proteínas Supressoras de Tumor/genética , Proteínas Supressoras de Tumor/metabolismo
3.
Spinal Cord ; 47(4): 312-7, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19015666

RESUMO

STUDY DESIGN: Retrospective 9-year survey. OBJECTIVES: Clinical presentation of acute myelitis syndromes is variable, and neuroimaging and laboratory findings are not specific enough to establish the diagnosis with certainty. We evaluated the spectrum clinical features and paraclinical findings encountered during diagnostic workup and aiding the diagnosis. SETTING: Department of Neurology, Inselspital Bern, Switzerland. MATERIAL: Charts and magnetic resonance imaging (MRI) of 63 patients discharged with the diagnosis of acute transverse myelitis. RESULTS: The diagnosis was supported by abnormal MRI and cerebrospinal fluid (CSF) findings in 52 patients (82.5%) and suspected in the remaining either because of a spinal cord MRI lesion suggestive of myelitis (n=5), or abnormal CSF findings (n=4), or electrophysiological evidence of a spinal cord dysfunction (n=2). Clinical impairment was mild (ASIA D) in the majority. All patients had sensory disturbances, whereas motor deficit and autonomic dysfunction were less frequent. Neurological levels were mainly located in cervical or thoracic dermatomes. Spinal cord lesions were visualized by MRI in 90.4% of the patients and distributed either in the cervical or thoracic cord, or both. Multiple lesions were present in more than half of the patients, and lateral, centromedullary and posterior locations were most common. A high percentage of multiple sclerosis (MS)-typical brain lesions and CSF findings suggested a substantial number of MS-related myelitis in our cohort. CONCLUSION: The diagnostic workup of acute myelitis discloses a broad spectrum of CSF or MRI findings, and may be associated with diagnostic uncertainty due to lack of specific CSF or MRI features, or pathological findings.


Assuntos
Imageamento por Ressonância Magnética/métodos , Mielite Transversa/diagnóstico , Mielite Transversa/fisiopatologia , Análise Espectral , Medula Espinal/patologia , Adolescente , Adulto , Proteína C-Reativa/metabolismo , Feminino , Humanos , Imunoglobulina G/metabolismo , Masculino , Pessoa de Meia-Idade , Mielite Transversa/líquido cefalorraquidiano , Exame Neurológico , Estudos Retrospectivos , Adulto Jovem
4.
Eur J Neurol ; 15(4): 398-405, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18312402

RESUMO

Acute partial transverse myelitis (APTM) may be the first clinical manifestation of multiple sclerosis (MS), of relapsing myelitis, or remain a monophasic event. Identification of risk factors associated with relapse or conversion to MS is important, as prognostic information might help to guide management. The objective of this study was to define clinical, laboratory and neuroimaging factors in patients with first-ever APTM that predict relapses or conversion to MS. We identified 73 patients with a first-ever APTM admitted to our institution from January 1999 to June 2005. The follow-up time ranged from 12 to 90 months (mean follow-up 46 months). Patient demographics, clinical impairment at onset and after 3 months, ancillary tests including cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), evoked potentials, recurrent and new symptoms and signs during follow-up were analysed. APTM remained a monophasic event in 35 patients (47.9%), conversion to MS occurred in 32 (43.8%) and recurred as relapsing myelitis in six patients (8.2%). According to univariate analysis, a family history of MS (P = 0.02), higher expanded disability status scale (EDSS) at onset (P = 0.03) and lesions on brain MRI (P = 0.03) were predictive factors for conversion to MS. CSF-specific oligoclonal bands (P = 0.04) or abnormal IgG-index (P = 0.04) were associated with increased risk for MS as well. In patients with a first-ever APTM, a family history of MS, high EDSS at presentation, lesions on brain MRI, CSF-specific oligoclonal bands or abnormal IgG-index may indicate an increased risk for conversion to MS.


Assuntos
Esclerose Múltipla/etiologia , Mielite Transversa/complicações , Fatores de Risco , Adulto , Idoso , Progressão da Doença , Eletroencefalografia/métodos , Potenciais Evocados Visuais/fisiologia , Feminino , Seguimentos , Humanos , Imunoglobulina G/sangue , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/líquido cefalorraquidiano , Esclerose Múltipla/imunologia , Esclerose Múltipla/patologia , Mielite Transversa/líquido cefalorraquidiano , Mielite Transversa/imunologia , Mielite Transversa/patologia , Exame Neurológico , Bandas Oligoclonais , Estudos Retrospectivos , Estatísticas não Paramétricas
5.
Int J Tuberc Lung Dis ; 9(2): 151-6, 2005 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15732733

RESUMO

OBJECTIVE: To describe the establishment and development of the National Tuberculosis Control Programme (NTP) of Vietnam. METHODS: Data were obtained from the surveillance system established by the new NTP in 1986 and based on the principles now described as the WHO DOTS strategy. RESULTS: The proportion of districts covered by the NTP increased from 40% in 1986 to almost 100% in 2000. The proportion of communes applying NTP guidelines increased from 18% in 1986 to 99.8% in 2000. The total number of tuberculosis cases notified increased from 8737 in 1986 to 89 792 in 2000. Most of these are new smear-positive cases. Based on WHO estimations of the incidence rate, the proportion of new smear-positive cases detected and put on short-course treatment has been over 70% since 1996. Reported cure rates with short-course chemotherapy are consistently over 85%. CONCLUSIONS: DOTS is feasible in a low-income, high-burden country. The main reasons for success were political commitment, a well-functioning health network, integration of tuberculosis control into the general health service at district level, a continuous supply of drugs and effective external support. Major challenges are long-term financial support, expansion to remote areas and vulnerable groups, definition of the role of the private sector, and future developments of the HIV epidemic and multidrug resistance.


Assuntos
Programas Nacionais de Saúde , Tuberculose/prevenção & controle , Humanos , Programas Nacionais de Saúde/organização & administração , Tuberculose/epidemiologia , Vietnã/epidemiologia
6.
Transplantation ; 69(11): 2343-53, 2000 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-10868638

RESUMO

BACKGROUND: Tacrolimus in combination with prednisolone has been proven to be a safe and effective immunosuppressive induction therapy in solid organ transplantation. However, it remains unclear whether a tacrolimus-based quadruple induction regimen with azathioprine and an antilymphocytic preparation could further improve the results after orthotopic liver transplantation. Therefore, we designed a prospective, randomized study to compare the immunosuppressive efficacy of dual (tacrolimus and prednisolone) and quadruple (tacrolimus, azathioprine, ALG Merieux and prednisolone) induction after liver transplantation. METHODS: After randomization, 120 consecutive patients of primary liver transplants were divided into the dual group (n=59) and the quadruple group (n=61) and followed for a minimum of 3 years. RESULTS: Patient survival at 3 years was 88.2% in the dual versus 94.9% in the quadruple group. Overall 25 patients in each group (41 and 42%, respectively) developed acute rejection. There was no difference in the number and severity of rejections. In each group only four patients required OKT3-therapy, however, although three of four patients in the quadruple group responded to OKT3 and cleared rejection, none of the four patients in the dual group were treated successfully with OKT3 (P<0.02). Rejection in these patients resolved only after additional treatment with mycophenolate mofetil. Adverse events and infections were equally distributed in both groups. Asymptomatic Cytomegalovirus infections were more common in the quadruple group (P<0.02). As of today, only one patient developed posttransplant lymphoproliferative disease (dual group). CONCLUSIONS: The data from our single-center study indicate that both tacrolimus-based dual and quadruple immunosuppressive induction regimens yield similar safety and effectiveness after liver transplantation.


Assuntos
Soro Antilinfocitário/uso terapêutico , Azatioprina/uso terapêutico , Glucocorticoides/uso terapêutico , Imunossupressores/uso terapêutico , Transplante de Fígado , Prednisolona/uso terapêutico , Tacrolimo/uso terapêutico , Adulto , Quimioterapia Combinada , Feminino , Rejeição de Enxerto/tratamento farmacológico , Rejeição de Enxerto/epidemiologia , Sobrevivência de Enxerto , Humanos , Incidência , Fígado/fisiopatologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Análise de Sobrevida
7.
Int J Oral Maxillofac Surg ; 27(5): 334-8, 1998 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-9804194

RESUMO

Titanium implants for the reconstruction of bony skull defects, using data from three-dimensional spiral computer tomography, have been described by other authors. Instead of milling the implants from a titanium block, an advanced method of rapid prototyping for a fine casting process is presented. Casting vs milling offers several advantages. It is possible to form very thinly tapered structures and to obtain more complex geometrical structures with smaller diameters. Many geometrical forms, which cannot be milled for technical reasons, can be produced using this technique.


Assuntos
Placas Ósseas , Desenho Assistido por Computador , Traumatismos Craniocerebrais/cirurgia , Craniotomia/instrumentação , Modelos Anatômicos , Próteses e Implantes , Adulto , Materiais Biocompatíveis , Craniotomia/métodos , Feminino , Humanos , Masculino , Planejamento de Assistência ao Paciente , Cimento de Policarboxilato , Terapia Assistida por Computador , Titânio , Tomografia Computadorizada por Raios X
8.
Br J Pharmacol ; 124(2): 277-82, 1998 May.
Artigo em Inglês | MEDLINE | ID: mdl-9641543

RESUMO

1. We administered the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin at a daily dose of 1 mg kg(-1) body weight to cholesterol-fed (0.03%) heterozygous Watanabe heritable hyperlipidaemic rabbits, an animal model for heterozygous familial hypercholesterolaemia. 2. After 12 months of cholesterol treatment, immunohistochemistry with the monoclonal antibody 9D9 was used to detect hepatic low density lipoprotein (LDL) receptors, which were quantified by densitometry. In addition we determined LDL receptor mRNA by competitive reverse transcriptase polymerase chain reaction. The cholesterol precursor lathosterol and the plant sterol campesterol were analysed by gas-liquid chromatography. 3. The drug reduced total plasma cholesterol levels by 51% (P=0.04), when compared to the control group. Unexpectedly, hepatic LDL receptor density and mRNA showed no significant differences between the groups. Total plasma levels of lathosterol and campesterol also revealed no significant differences between the groups, if expressed relative to plasma cholesterol. 4. The findings suggest that mechanisms other than induced hepatic LDL receptors are responsible for the cholesterol-lowering effect of pravastatin in this animal model. We propose a reduced cholesterol absorption efficiency compatible with similar campesterol levels between both groups observed in our study.


Assuntos
Anticolesterolemiantes/farmacologia , Colesterol/sangue , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Fígado/efeitos dos fármacos , Fitosteróis , Pravastatina/farmacologia , Animais , Anticolesterolemiantes/administração & dosagem , Colesterol/análogos & derivados , Colesterol na Dieta/administração & dosagem , Heterozigoto , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Hiperlipoproteinemia Tipo II/sangue , Imuno-Histoquímica , Absorção Intestinal/efeitos dos fármacos , Fígado/metabolismo , Reação em Cadeia da Polimerase , Pravastatina/administração & dosagem , RNA Mensageiro/análise , Coelhos , Receptores de LDL/genética , Receptores de LDL/metabolismo
9.
Clin Biochem ; 31(1): 37-45, 1998 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-9559223

RESUMO

OBJECTIVES: Primary prevention trials of antihypertensive therapy have shown conflicting results on coronary events. Potential interference of antihypertensive agents with cellular lipid metabolism may alter the atherosclerotic risk of individuals. DESIGN AND METHODS: The effects of the calcium antagonist's verapamil, diltiazem, and nifedipine and of the beta-blockers propranolol and metoprolol on low density lipoprotein (LDL) receptor activity, cholesterol esterification rate, oleate incorporation in triglycerides and sterol synthesis were studied in freshly isolated human leukocytes and HEP G2 cells. RESULTS: Up to a concentration of 3-10 mumol/L, verapamil, propranolol, and metoprolol led to an increased cellular content of 125I-LDL by an inhibition of degradation. In mononuclear cells verapamil stimulated accumulation and degradation. No effect on binding was observed. Diltiazem was only stimulatory on 125I-LDL processing in leukocytes. Beta blockers and verapamil significantly reduced the LDL mediated 14C-oleate incorporation in cholesterol esters. In the presence of 25-hydroxycholesterol the esterification was not diminished, which suggests that cholesterolacyltransferase (ACAT) was not affected per se. Whereas all the agents induced the synthesis of lanosterol, metoprolol inhibited cholesterol synthesis. None of the agents had a significant influence on 14C-oleate incorporation in triglycerides, suggesting a specific influence on cholesterol metabolism. CONCLUSIONS: Antihypertensive drugs affect the cholesterol metabolism on a cellular level. Mechanisms are an interference with degradation of LDL and consequent alterations of cholesterol esterification. Using leukocytes as peripheral cells and HEP G2 as a model of human liver, these results may have importance when antihypertensive long-term therapy is conducted for primary or secondary prevention of atherosclerotic complications.


Assuntos
Anti-Hipertensivos/farmacologia , Carcinoma Hepatocelular/metabolismo , Colesterol/metabolismo , Leucócitos Mononucleares/efeitos dos fármacos , Leucócitos Mononucleares/metabolismo , Neoplasias Hepáticas/metabolismo , Diltiazem/farmacologia , Humanos , Metoprolol/farmacologia , Nifedipino/farmacologia , Propranolol/farmacologia , Células Tumorais Cultivadas , Verapamil/farmacologia
10.
Circulation ; 96(6): 1809-18, 1997 Sep 16.
Artigo em Inglês | MEDLINE | ID: mdl-9323066

RESUMO

BACKGROUND: Platelet interaction with endothelium plays an important role in the pathophysiology of coronary microcirculation. We assessed the role of the vitronectin receptor (integrin alpha(v)beta3) in platelet/endothelium adhesion. METHODS AND RESULTS: We investigated the effect on platelet/endothelium adhesion of plasma obtained from patients with acute myocardial infarction during reperfusion (before and 8, 24, 48, and 72 hours and 5 to 7 days after direct angioplasty) and with pretreatment with alpha-thrombin (2 U/mL) and recombinant human interleukin-1beta. Platelet/endothelium adhesion was significantly enhanced by approximately 20% after pretreatment of endothelium with patient plasma for 4 hours (P<.05) compared with endothelium treated with pooled control plasma. Plasma-induced platelet/endothelium adhesion was, in part, RGD peptide dependent. Pretreatment of endothelial cells with alpha-thrombin or recombinant human interleukin-1beta enhanced platelet/endothelium adhesion and surface expression of alpha(v)beta3 on the luminal aspect of endothelium (P<.05). The adhesion of platelets, isolated platelet microparticles, and Chinese hamster ovary cells bearing human recombinant alpha(IIb)beta3 (platelet glycoprotein IIb-IIIa) to activated endothelial cells was inhibited by antiadhesive peptides GRGDSP and c(RGDfV) and monoclonal antibodies 4F10, LM609, and 7E3. CONCLUSIONS: The expression of vitronectin receptor exposed on the luminal aspect of activated endothelium is enhanced and mediates platelet/endothelium adhesion. Vitronectin receptor-mediated platelet attachment to activated endothelium during reperfusion may contribute to reperfusion injury and could be a target for antiadhesive therapy.


Assuntos
Endotélio Vascular/química , Infarto do Miocárdio/complicações , Traumatismo por Reperfusão Miocárdica/metabolismo , Adesividade Plaquetária/fisiologia , Receptores de Vitronectina/metabolismo , Adulto , Idoso , Animais , Antígenos de Superfície/metabolismo , Proteínas Sanguíneas/farmacologia , Células CHO/química , Células CHO/citologia , Células CHO/fisiologia , Adesão Celular/fisiologia , Células Cultivadas , Cricetinae , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/ultraestrutura , Feminino , Humanos , Peptídeos e Proteínas de Sinalização Intercelular , Masculino , Microscopia Eletrônica , Pessoa de Meia-Idade , Traumatismo por Reperfusão Miocárdica/etiologia , Oligopeptídeos/farmacologia , Peptídeos/farmacologia , Inibidores da Agregação Plaquetária/farmacologia , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/genética , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/metabolismo , Proteínas Recombinantes/metabolismo , Veias Umbilicais/citologia
11.
Z Gastroenterol ; 34 Suppl 3: 127-8, 1996 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8767488

RESUMO

A rapid and sensitive method of quantifying very low-abundant mRNA species by competitive reverse transcriptase-polymerase chain reaction (cRT-PCR) is presented. For each analysis, a defined amount of total cellular RNA is co-reverse transcribed and co-amplified with a titration series of in vitro synthesized RNA from a clone of the mRNA which carries an internal deletion. The equivalence point, which defines the number of specific mRNA molecules in the sample, can be determined using ethidium bromide stained gels of the reaction products. We present here three examples of the application of this new technique to the quantification of the low abundant mRNA for the low density lipoprotein (LDL) receptor. First, the regulation of LDL receptor mRNA expression by the HMG-CoA reductase inhibitor, pravastatin, has been analysed in vitro, in a human gastric tumour cell line. Second, LDL receptor mRNA from various bovine tissues has been quantified. Third, the expression of LDL receptor mRNA in human tissues originating from colorectal carcinoma and corresponding tumour-tree margins of surgical specimens has been measured.


Assuntos
Expressão Gênica/fisiologia , Reação em Cadeia da Polimerase/métodos , Receptores de LDL/genética , Animais , Bovinos , Linhagem Celular , Neoplasias Colorretais/genética , Humanos , Hiperlipoproteinemia Tipo II/genética , Especificidade de Órgãos , RNA Mensageiro/genética , Neoplasias Gástricas/genética
12.
Int J Cancer ; 61(4): 461-4, 1995 May 16.
Artigo em Inglês | MEDLINE | ID: mdl-7759150

RESUMO

It is currently under debate whether the low serum cholesterol levels that are frequently observed in cancer patients represent a risk factor for/or, rather, are a consequence of the tumour. We postulate that malignant tumours are directly involved in an increased catabolism of cholesterol-rich low-density lipoprotein (LDL) particles. In a prospective study of 25 patients with colorectal carcinoma, we measured intraindividual shifts in serum cholesterol levels after surgery, and the expression of LDL-receptor mRNA in surgically removed specimens. A significant rise in plasma cholesterol levels was observed in patients 3 and 12 months after curative surgery, but not after non-curative surgery. In human colon carcinoma tissues LDL receptor mRNA expression, as determined by competitive reverse-transcriptase-polymerase-chain reaction, was found to be significantly increased when compared to tissues from the tumour-free margin (median values, 1.2 x 10(6) vs. 2.0 x 10(5) molecules/micrograms total cellular RNA, respectively, n = 17). The extent of LDL-receptor mRNA expression positively correlated to the percentage rise of plasma cholesterol levels 3 months (n = 7, r = 0.8763) and 12 months (n = 6, r = 0.9181) after curative surgery. This finding provides in vivo evidence that the tumour tissue itself contributes to decreased plasma cholesterol levels in patients suffering from colorectal carcinomas. It supports the hypothesis that low cholesterol levels in cancer patients are a consequence, and not the cause, of the malignancy.


Assuntos
Colesterol/sangue , Neoplasias do Colo/sangue , Neoplasias do Colo/cirurgia , RNA Mensageiro/metabolismo , Receptores de LDL/biossíntese , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias do Colo/ultraestrutura , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , RNA Mensageiro/genética , Receptores de LDL/genética
13.
J Cancer Res Clin Oncol ; 121(6): 343-9, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-7797599

RESUMO

Competitive inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase are currently used to treat patients with hypercholesterolaemia. These inhibitors affect not only cholesterol biosynthesis, but also the production of non-steroidal mevalonate derivatives, that are involved in a number of growth-regulatory processes. As a consequence, their potential use as anticancer drugs has been suggested. In order to examine long-term effects of this potential therapeutic approach, we cultivated the gastric carcinoma cell line, EPG85-257, and the breast tumour cell line, MDA-MB231, in the presence of increasing concentrations of the HMG-CoA reductase inhibitor, pravastatin. For both cell lines, this procedure led to the selection of resistant variants able to proliferate in more than 1000 microM inhibitor. By competitive reverse transcriptase/polymerase chain reaction assay (cRT-PCR), the expression of the mRNA for two key proteins of cellular cholesterol metabolism, HMG-CoA reductase and low-density lipoprotein (LDL) receptor, were analysed in sensitive and resistant cells. Despite similar growth rates, MDA-MB231 cells expressed approximately four times more HMG-CoA reductase mRNA than EPG85-257 cells and over 30 times more LDL receptor mRNA. Both mRNA species were coordinately regulated in the parental and in the pravastatin-resistant variant cells. Expression was highly stimulated (3- to 4-fold for the HMG-CoA reductase and 2- to 3-fold for the LDL receptor) in the resistant variants when cultured in lipoprotein-deficient medium in the presence of 1000 microM pravastatin. Immunocytological analysis of the expression of the HMG-CoA reductase and LDL receptor protein were in accordance with the data on specific mRNA expression obtained by cRT-PCR. Southern blot analysis revealed a 1.5-fold amplification of the HMG-CoA reductase gene in resistant MDA-MB231 cells, but not in the resistant EPG85-257 variant. Our data provide evidence for resistance mechanisms to pravastatin that are independent of the amplification of the HMG-CoA reductase gene. By analogy to the cell-culture models employed in this study, it is conceivable that similar mechanisms might occur in human tumour cells in vivo during long-term treatment with HMG-CoA reductase inhibitors. This might limit their application as chemotherapeutic anticancer agents.


Assuntos
Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , LDL-Colesterol/metabolismo , Pravastatina/farmacologia , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/patologia , Southern Blotting , Neoplasias da Mama/enzimologia , Divisão Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Expressão Gênica/efeitos dos fármacos , Humanos , Hidroximetilglutaril-CoA Redutases/efeitos dos fármacos , Imuno-Histoquímica , Reação em Cadeia da Polimerase/métodos , RNA Mensageiro/efeitos dos fármacos , RNA Neoplásico/efeitos dos fármacos , Neoplasias Gástricas/enzimologia , Células Tumorais Cultivadas
14.
J Lipid Res ; 35(6): 976-81, 1994 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-7521386

RESUMO

A rapid method for quantifying the low-abundant mRNAs of the low density lipoprotein receptor and the 3-hydroxy-3-methylglutaryl coenzyme A reductase by competitive polymerase chain reaction is presented. This approach requires neither special labeling nor blotting procedures. For each analysis, a defined amount of total cellular RNA is co-reverse transcribed and co-amplified with a titration series of in vitro synthesized competitor RNA that carries an internal deletion. The equivalence point, which defines the amount of specific RNA in the sample, can be scored in ethidium bromide-stained agarose or polyacrylamide gels of the reaction products. As an example, responses to pravastatin, a competitive inhibitor of the HMG-CoA reductase, in a human tumor cell line were analyzed with this new technique. As a control, the expression of the unregulated gene, glyceraldehyde-3-phosphate dehydrogenase was measured in parallel using the same methodology. The results obtained were compared with those obtained by conventional Northern blotting.


Assuntos
Etídio , Reação em Cadeia da Polimerase , RNA Mensageiro/análise , DNA Polimerase Dirigida por RNA , Coloração e Rotulagem , Sequência de Bases , Ligação Competitiva , Northern Blotting , Expressão Gênica , Gliceraldeído-3-Fosfato Desidrogenases/genética , Humanos , Hidroximetilglutaril-CoA Redutases/genética , Dados de Sequência Molecular , Receptores de LDL/genética , Neoplasias Gástricas , Células Tumorais Cultivadas
15.
Clin Investig ; 70(8): 683-5, 1992 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-1392445

RESUMO

Twenty-two patients with acute myeloblastic leukaemia (AML) were studied to investigate disease-associated changes in lipid metabolism. Lipoprotein (a) [Lp(a)] levels were found to be elevated at the time of diagnosis (median 23 mg/dl; 41% of patient group had levels greater than 25 mg/dl) and diminished after successful chemotherapeutic treatment in 9 of 10 cases, with a maximum decrease from 56 to 10 mg/dl. In contrast, reduced levels of total cholesterol, low density lipoprotein (LDL) and high density lipoprotein (HDL) (medians 137, 87 and 20 mg/dl, respectively) were observed at the time of diagnosis. Cholesterol and HDL levels increased in all 10 and LDL in 9 cases in which complete remission was achieved. These data suggest that the catabolism of LDL-cholesterol might be even more enhanced than assumed to date. Furthermore, it indicates that the Lp(a) level in acute myeloblastic leukaemia is influenced either directly or indirectly by the leukaemic blasts.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia Mieloide Aguda/sangue , Lipoproteína(a)/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Colesterol/sangue , Feminino , Seguimentos , Humanos , Leucemia Mieloide Aguda/tratamento farmacológico , Masculino , Pessoa de Meia-Idade
16.
Biochem Biophys Res Commun ; 181(3): 1479-85, 1991 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-1722405

RESUMO

Pertussis toxin is an ADP-ribosyltransferase which alters the function of some of the GTP-binding proteins and inhibits some actions of insulin. In vivo, pertussis toxin (2 micrograms/ml/2h) inhibited insulin-stimulated tyrosyl autophosphorylation of the insulin receptor by 50% in FaO cells, and nearly completely inhibited phosphorylation of the cellular insulin receptor substrate pp185. Similarly, insulin-stimulated autophosphorylation and kinase activity of the insulin receptor purified on wheat germ agglutinin-agarose from pertussis toxin-treated FaO cells was diminished 50%; however, treatment of cells with the catalytically inactive B-oligomer of the toxin had no effect on receptor tyrosine kinase activity in vitro. Pertussis toxin did not alter insulin binding or the cellular levels of ATP, cAMP, and cGMP. Furthermore, immunoprecipitation of the insulin receptor from intact cells with anti-insulin receptor antibodies showed that pertussis toxin did not increase the phosphorylation of serine or threonine residues in the insulin receptor. These results suggest that pertussis toxin can modulate signal transduction of insulin at the level of the insulin receptor kinase.


Assuntos
Toxina Pertussis , Proteínas Tirosina Quinases/metabolismo , Receptor de Insulina/metabolismo , Fatores de Virulência de Bordetella/farmacologia , Animais , Linhagem Celular , Ativação Enzimática , Insulina/metabolismo , Insulina/farmacologia , Cinética , Neoplasias Hepáticas Experimentais , Peso Molecular , Fosfoproteínas/isolamento & purificação , Fosforilação , Fosfotirosina , Proteínas Tirosina Quinases/antagonistas & inibidores , Ratos , Receptor de Insulina/efeitos dos fármacos , Tirosina/análogos & derivados , Tirosina/análise
17.
Oncogene ; 4(6): 753-7, 1989 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-2543944

RESUMO

Aberrations in nuclear proto-oncogene organisation and/or gene expression have been implicated in cell transformation mediated by the v-abl gene. For example, it has been suggested that amplification of the c-myc proto-oncogene is a co-operative event in v-abl induced fibroblast transformation. We have investigated amplification of the c-myc, p53 and c-fos nuclear proto-oncogenes in several Abelson murine leukaemia virus (A-MuLV) transformed fibroblast lines. None of these proto-oncogenes were detectably rearranged or amplified in v-abl transformed Swiss 3T3 lines. In contrast, NIH3T3 fibroblasts transformed by the v-abl gene consistently showed a 4 to 16-fold amplification of the c-myc gene. These data show that c-myc gene amplification is not an obligatory event associated with A-MuLV transformation, but may be restricted to cell lines derived from NIH3T3. c-myc gene amplification also did not correlate with a reduced latency period for tumour induction in nude mice. In addition, c-myc amplification was not selected during tumourigenesis, indicating that this event is not required for A-MuLV transformed Swiss 3T3 cells to display a full tumourigenic phenotype.


Assuntos
Vírus da Leucemia Murina de Abelson/genética , Fibroblastos/microbiologia , Amplificação de Genes , Vírus da Leucemia Murina/genética , Proto-Oncogenes , Animais , Southern Blotting , Linhagem Celular Transformada , Fibroblastos/ultraestrutura , RNA Mensageiro/biossíntese
18.
EMBO J ; 5(9): 2191-5, 1986 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-3023060

RESUMO

Cells transformed by the v-abl-oncogene produce large amounts of the tumour growth factor alpha TGF. alpha TGF is homologous to the epidermal growth factor (EGF) and stimulates cell growth via the EGF receptor pathway. To separate metabolic events in the v-abl-transformed cells mediated by alpha TGF as opposed to the v-abl-encoded protein-tyrosine kinase, we have employed the Swiss 3T3 variant cell line NR6 which lacks a functional EGF receptor. v-abl was found to transform efficiently NR6 cells in vitro. These transformed NR6 cells displayed a variety of in vitro properties which were indistinguishable from transformed wild-type fibroblast lines. However, in contrast to the wild-type lines, v-abl-transformed NR6 cells failed to form tumours when injected into athymic nude mice. These results imply an important function for alpha TGF and the EGF receptor in the establishment of the v-abl-induced fibrosarcomas.


Assuntos
Vírus da Leucemia Murina de Abelson/genética , Transformação Celular Neoplásica , Transformação Celular Viral , Receptores ErbB/genética , Vírus da Leucemia Murina/genética , Oncogenes , Animais , Células Cultivadas , Fibroblastos/citologia , Imunofluorescência , Genes Virais , Camundongos , Camundongos Nus , Proteínas Tirosina Quinases/análise
19.
EMBO J ; 4(12): 3173-8, 1985 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-3004937

RESUMO

The transforming protein of the Abelson murine leukaemia virus encodes a protein-tyrosine kinase. Previously, we have shown that in Abelson-transformed cells, the Abelson kinase regulates the phosphoserine content of ribosomal protein S6. Phorbol 12-myristate 13-acetate (TPA), which activates protein kinase C, induces the phosphorylation of S6 at the same five phosphopeptides as found in S6 isolated from Abelson-transformed cells. We have investigated three models whereby the Abelson kinase might regulate S6 phosphorylation via the activation of protein kinase C. First, the Abelson kinase could phosphorylate protein kinase C on tyrosine. However, we do not detect significant amounts of phosphotyrosine in protein kinase C in vivo. Second, it has been suggested that protein-tyrosine kinases might phosphorylate phosphatidylinositol. This could increase the intracellular levels of diacylglycerol and thereby activate protein kinase C. Our data strongly suggest that direct phosphorylation of phosphatidylinositol by the Abelson protein-tyrosine kinase has no physiological role. Third, an indirect activation of protein kinase C may occur via an increase in the rate of phosphoinositide breakdown. We have found that phosphoinositide breakdown appears to be constitutively activated in Abelson-transformed cells. The implications of these observations are discussed with regard to S6 phosphorylation and the mechanism of Abelson-induced transformation.


Assuntos
Vírus da Leucemia Murina de Abelson/genética , Transformação Celular Neoplásica , Genes Virais , Genes , Vírus da Leucemia Murina/genética , Fosfatidilinositóis/metabolismo , Proteínas Tirosina Quinases/genética , Trifosfato de Adenosina/metabolismo , Animais , Linhagem Celular , Células Cultivadas , Cinética , Camundongos , Camundongos Endogâmicos , Radioisótopos de Fósforo , Fosforilação , Proteínas Tirosina Quinases/metabolismo
20.
J Mol Biol ; 174(2): 297-317, 1984 Apr 05.
Artigo em Inglês | MEDLINE | ID: mdl-6325711

RESUMO

We have used the method of chemical crosslinking in order to determine the spatial interactions between components of Rous sarcoma virus. A high molecular weight complex formed by crosslinking has been isolated by ultracentrifugation on sucrose density gradients containing 0.1% (w/v) sodium dodecyl sulphate. This complex is composed of the two viral glycoproteins gp85 and gp35, the gag protein p19, and the viral RNA. Two types of bonding are important for the formation and stability of the complex: first, native disulphide bonds between gp85 and gp35 and between individual p19 molecules; and second, hetero-crosslinking between gp35 and p19 as well as homo-crosslinking between p19. Although viral RNA is quantitatively present in the complex, experiments with RNase treatment show that it is not essential for its formation or stability. A small amount of lipid is present in the complex and appears to be crosslinked to p19. In vitro-labelling of purified virus with the lipophilic photoactivatable reagent [125I] iodonaphthylazide resulted in the labelling of gp35 and p19/23. In vivo-labelling of virus with [3H]palmitate resulted in only gp35 becoming labelled. These results substantiate the membrane association of these proteins. The significance of the interactions in the high molecular weight complex for the stability of the virus and, by implication, the role which they may play in viral assembly are discussed.


Assuntos
Vírus do Sarcoma Aviário/metabolismo , Proteínas do Envelope Viral/metabolismo , Proteínas Virais/metabolismo , Centrifugação com Gradiente de Concentração , Reagentes de Ligações Cruzadas , Dissulfetos , Eletroforese em Gel de Poliacrilamida , Produtos do Gene gag , Técnicas Imunológicas , Substâncias Macromoleculares , Peso Molecular , Tripsina , Proteínas do Core Viral , Proteínas Virais/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA